Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

Oriol Casanovas; Daniel J. Hicklin; Gabriele Bergers; Douglas Hanahan

doi:10.1016/j.ccr.2005.09.005

Back

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

Article 2005 en

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2002

Combining Antiangiogenic Agents with Metronomic Chemotherapy Enhances Efficacy against Late-stage Pancreatic Islet Carcinomas in Mice

Gabriele Bergers, Douglas Hanahan

Article2003

Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis

Johanna A. Joyce, Pirjo Laakkonen, Michele Bernasconi, Gabriele Bergers, Erkki Ruoslahti, Douglas Hanahan

Article2011

Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition

Elizabeth Allen, Ian Walters, Douglas Hanahan

Article2007

Measurement of pancreatic islet cell proliferation by heavy water labeling

Songyuan Chen, Scott Turner, Ellen Tsang, Julie M. Stark, Holly Turner, Ablatt Mahsut, Keri Keifer, Michelle Goldfinger, Marc Hellerstein

Article2005

Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways

Qing Xu, Jon Briggs, Sungman Park, Guilian Niu, Marcin Kortylewski, Shumin Zhang, Tanya Gritsko, James Turkson, H. David Kay, Gregg L. Friedman, Jin Cheng, Richard Jove, Hua Yu